Last reviewed · How we verify
Pneumococcal Vaccine Polyvalent-Pneumovax 23
At a glance
| Generic name | Pneumococcal Vaccine Polyvalent-Pneumovax 23 |
|---|---|
| Sponsor | Sanofi |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (PHASE3)
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) (PHASE3)
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months (PHASE2)
- Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal Vaccine Polyvalent-Pneumovax 23 CI brief — competitive landscape report
- Pneumococcal Vaccine Polyvalent-Pneumovax 23 updates RSS · CI watch RSS
- Sanofi portfolio CI